BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32153656)

  • 1. Computational analyses on genetic alterations in the NSD genes family and the implications for colorectal cancer development.
    D'Afonseca V; Gónzalez G; Salazar M; Arencibia AD
    Ecancermedicalscience; 2020; 14():1001. PubMed ID: 32153656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancers and the NSD family of histone lysine methyltransferases.
    Morishita M; di Luccio E
    Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
    Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
    Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
    Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
    Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
    Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
    Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of NSD2 and NSD3 in overgrowth syndromes.
    Douglas J; Coleman K; Tatton-Brown K; Hughes HE; Temple IK; Cole TR; Rahman N;
    Eur J Hum Genet; 2005 Feb; 13(2):150-3. PubMed ID: 15483650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NSD family of protein methyltransferases in human cancer.
    Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
    Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma.
    Murali M; Saloura V
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic perturbations of SETD2, NSD1, NSD2, NSD3 and ASH1L reveals their distinct contributions to H3K36 methylation.
    Shipman GA; Padilla R; Horth C; Hu B; Bareke E; Vitorino FN; Gongora JM; Garcia BA; Lu C; Majewski J
    bioRxiv; 2023 Oct; ():. PubMed ID: 37905045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
    Morishita M; di Luccio E
    Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
    Bennett RL; Swaroop A; Troche C; Licht JD
    Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.
    Rathert P
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
    Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
    Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMR backbone resonance assignment and solution secondary structure determination of human NSD1 and NSD2.
    Amin N; Nietlispach D; Qamar S; Coyle J; Chiarparin E; Williams G
    Biomol NMR Assign; 2016 Oct; 10(2):315-20. PubMed ID: 27356987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High yield recombinant expression and purification of oncogenic NSD1, NSD2, and NSD3 with human influenza hemagglutinin tag.
    Shen Y; Morishita M; di Luccio E
    Protein Expr Purif; 2020 Feb; 166():105506. PubMed ID: 31563542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nizp1 is a specific NUP98-NSD1 functional interactor that regulates NUP98-NSD1-dependent oncogenic programs.
    Berardi A; Botrugno OA; Quilici G; Manteiga JMG; Bachi A; Tonon G; Musco G
    FEBS J; 2023 Apr; 290(7):1782-1797. PubMed ID: 36271682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alteration of histone lysine methyltransferases and their significance in renal cell carcinoma.
    Yan L; Zhang Y; Ding B; Zhou H; Yao W; Xu H
    PeerJ; 2019; 7():e6396. PubMed ID: 30755832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Computational Approach to Predict the Role of Genetic Alterations in Methyltransferase Histones Genes With Implications in Liver Cancer.
    Aravena TI; Valdés E; Ayala N; D'Afonseca V
    Cancer Inform; 2023; 22():11769351231161480. PubMed ID: 37008071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone Methyltransferases Useful in Gastric Cancer Research.
    Reyes DA; Sarría VMS; Salazar-Viedma M; D'Afonseca V
    Cancer Inform; 2021; 20():11769351211039862. PubMed ID: 34413625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.